Back to today’s briefing

Story perspectives

Vistagen Launches Phase 2 Trial for Social Anxiety Spray

1/7/2025

44 10

Summary

Story summary

Vistagen, a biotech company from South San Francisco, has launched a Phase 2 study for fasedienol, a groundbreaking nasal spray designed to combat social anxiety disorder (SAD). This innovative trial will evaluate the drug's effectiveness and safety in real-life public speaking scenarios, potentially paving the way for the first FDA-approved acute treatment for those struggling with SAD.

1 of 1

Story summary

Vistagen, a biotech company from South San Francisco, has launched a Phase 2 study for fasedienol, a groundbreaking nasal spray designed to combat social anxiety disorder (SAD). This innovative trial will evaluate the drug's effectiveness and safety in real-life public speaking scenarios, potentially paving the way for the first FDA-approved acute treatment for those struggling with SAD.